MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

51.52 +0.55 (+1.09%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,014,799
Open 51.00
Bid (Size) 51.51 (2,100)
Ask (Size) 51.52 (700)
Prev. Close 50.96
Today's Range 50.92 - 52.12
52wk Range 35.12 - 71.28
Shares Outstanding N/A
Dividend Yield 4.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗
Will this pharma company become a new leader in the weight loss market? 
Via The Motley Fool
News headline image
Where Will Novo Nordisk Stock Be in 3 Years? ↗
Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while. 
Via The Motley Fool

Performance

YTD
-1.7%
-1.7%
1 Month
+6.6%
+6.6%
3 Month
+25.1%
+25.1%
6 Month
-18.1%
-18.1%
1 Year
-25.3%
-25.3%

More News

Read More
News headline image
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗
Via The Motley Fool
Topics Lawsuit
News headline image
2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
Via The Motley Fool
News headline image
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
Topics Lawsuit
News headline image
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗
Via The Motley Fool
Topics Lawsuit
News headline image
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗
Via The Motley Fool
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
Via FinancialNewsMedia
News headline image
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
Via The Motley Fool
News headline image
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗
Via The Motley Fool
News headline image
3 High-Yield Dividend Stocks to Buy and Hold ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
This GLP-1 Stock Could Double by 2030. Here's Why ↗
Via The Motley Fool
News headline image
2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗
Via The Motley Fool
News headline image
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
Via The Motley Fool
News headline image
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗
Via The Motley Fool
News headline image
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week ↗
Via The Motley Fool
News headline image
Is It Too Late to Buy Eli Lilly? ↗
Via The Motley Fool
News headline image
Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗
Via The Motley Fool
News headline image
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗
Via The Motley Fool
Topics Supply Chain
News headline image
3 Reasons to Buy Novo Nordisk Stock ↗
Via The Motley Fool
News headline image
U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗
Via The Motley Fool

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 51.52
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 07/29/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story